首页分享 Willow宣布与全球原料制造商合作，为大容量活性药物成分开发更具成本效益的可持续工艺

Willow宣布与全球原料制造商合作，为大容量活性药物成分开发更具成本效益的可持续工艺

来源：花匠小妙招时间：2025-08-13 18:40

SUNNYVALE, Calif., Jan. 31, 2024 /PRNewswire/ - Willow Biosciences Inc. ('Willow') (TSX: WLLW) (OTCQB: CANSF), a leading biotechnology company focused on revolutionizing industrial manufacturing of pure, consistent, and sustainable ingredients, today announced a collaboration with a leading Active Pharmaceutical Ingredient ('API') manufacturer to develop a more sustainable, cost-effective manufacturing route for their largest product sold globally..

加利福尼亚州桑尼维尔（SUNNYVALE），2024年1月31日/新闻专线/-Willow Biosciences Inc.（“Willow”）（TSX:WLLW）（OTCQB:CANSF），一家领先的生物技术公司，专注于彻底改变纯，一致和可持续成分的工业制造，今天宣布与领先的活性药物成分（“API”）制造商合作，以开发更可持续的，为其全球销售的最大产品提供经济高效的制造路线。。

Willow's collaboration partner, who currently holds a significant world market share of the API market, recognized the need to employ more sustainable methods to manufacture its APIs with reduced cost and less waste and sought Willow's expertise in developing and scaling a manufacturing process for this key ingredient.

Willow的合作伙伴目前在原料药市场上占有重要的世界市场份额，他们认识到需要采用更可持续的方法来生产成本更低、浪费更少的原料药，并寻求Willow在开发和扩大这种关键成分的制造工艺方面的专业知识。

The new partnership program will focus on optimization of an existing commercial biomanufacturing process for improved performance at scale. The development phase of this funded collaboration is expected to last approximately six months with additional milestone payments to be made for achieving defined performance targets..

新的合作伙伴计划将侧重于优化现有的商业生物制造过程，以提高规模性能。这项资助合作的开发阶段预计将持续约六个月，并将支付额外的里程碑付款，以实现既定的绩效目标。。

'We are excited to once again apply our technology platform to the manufacture of more sustainable APIs for existing, large volume global markets,' said Dr. Chris Savile, Willow's President & CEO. 'If successful, we believe that these ingredients essential for human health can be made more broadly available and more efficiently while also delivering significant value to our partner and shareholders.'.

Willow总裁兼首席执行官克里斯·萨维尔（ChrisSavile）博士说，我们很高兴再次将我们的技术平台应用于为现有的大容量全球市场制造更可持续的API如果成功，我们相信这些对人类健康至关重要的成分可以更广泛，更有效地获得，同时也为我们的合作伙伴和股东带来重大价值。”。

This agreement represents the second new development agreement executed by Willow in only the first few weeks of 2024, with a robust pipeline of other potential collaborations in process.

该协议是Willow在2024年前几周签署的第二份新开发协议，其他潜在合作正在进行中。

About Willow Biosciences Inc.

关于Willow Biosciences Inc。

Willow develops and produces precision fermented functional ingredients for the health and wellness, food and beverage and personal care markets. Willow's FutureGrown™ and BioOxi™ platforms enable large-scale production with sustainability at its core. Willow's R&D team has a proven track record of developing and commercializing bio-based manufacturing processes and products to benefit our B2B partners and their customers.

Willow为健康和保健、食品和饮料以及个人护理市场开发和生产精密发酵功能成分。柳树的未来™ 和BioOxi™ 平台以可持续性为核心实现大规模生产。Willow的研发团队在开发和商业化基于生物的制造工艺和产品方面有着良好的记录，以使我们的B2B合作伙伴及其客户受益。

For more information, visit www.willowbio.com..

欲了解更多信息，请访问www.willowbio.com。。

FutureGrown™ and BioOxi™ are registered trademarks of Willow Biosciences Inc. All other trademarks are trademarks of their respective holders.

未来成长™ 和BioOxi™ 是Willow Biosciences Inc.的注册商标。所有其他商标均为其各自持有人的商标。

Forward-Looking Statements

前瞻性声明

This news release may include forward-looking statements including opinions, assumptions, estimates and the Company's assessment of future plans and operations, and, more particularly, statements concerning: the development programs with its biopharma partner, including the ability to accommodate new programs and to expand capabilities;; the demand and market size potential of the synthetic ingredients industry; and the business plan of the Company, generally, including becoming a leader in precision fermentation, research and production of functional ingredients.

本新闻稿可能包括前瞻性声明，包括意见、假设、估计以及公司对未来计划和运营的评估，尤其是有关以下方面的声明：与其生物制药合作伙伴的发展计划，包括适应新计划和扩大能力的能力；；合成原料行业的需求和市场规模潜力；以及公司的商业计划，一般来说，包括成为精密发酵、功能成分研究和生产的领导者。

When used in this news release, the words 'will,' 'anticipate,' 'believe,' 'estimate,' 'expect,' 'intent,' 'may,' 'project,' 'should,' and similar expressions are intended to be among the statements that identify forward-looking statements. The forward-looking statements are founded on the basis of expectations and assumptions made by the Company which include, but are not limited to: the success of Willow's strategic partnerships, including the development of future strategic partnerships; the financial strength of the Company; the ability of the Company to fund its business plan using cash on hand and existing resources; the market for Willow's products; the ability of the Company to obtain and retain applicable licences; the ability of the Company to obtain suitable manufacturing partners and other strategic relationships; and the successful implementation of Willow's commercialization and production strategy, generally.

在本新闻稿中使用的词语“将”、“预期”、“相信”、“估计”、“预期”、“意图”、“可能”、“项目”、“应该”以及类似的表达都是用来识别前瞻性陈述的。前瞻性陈述基于公司的期望和假设，包括但不限于：Willow战略合作伙伴关系的成功，包括未来战略合作伙伴关系的发展；公司的财务实力；公司利用现有现金和现有资源为其商业计划提供资金的能力；柳树产品市场；公司获得和保留适用许可证的能力；公司获得合适的制造合作伙伴和其他战略关系的能力；以及柳树商业化和生产战略的成功实施。

Forward-looking statements are subject to a wide range of risks and uncertainties, and although the Company believes that the expectations represented by such forward-looking statements are reasonable, there can be no assurance that such expectations will be realized. Any number of importan.

前瞻性陈述受到广泛的风险和不确定性的影响，尽管公司认为此类前瞻性陈述所代表的期望是合理的，但无法保证此类期望会实现。任何数量的重要信息。

The forward-looking statements contained in this news release are made as of the date hereof and the Company does not undertake any obligation to update publicly or to revise any of the included forward-looking statements, except as required by applicable law. The forward-looking statements contained herein are expressly qualified by this cautionary statement..

本新闻稿中包含的前瞻性声明是在本新闻稿发布之日做出的，除适用法律要求外，公司不承担任何公开更新或修订任何包含的前瞻性声明的义务。本警示声明明确限定了本文所含的前瞻性声明。。

SOURCE Willow Biosciences Inc.

来源：Willow Biosciences Inc。